JP2023548858A5 - - Google Patents
Info
- Publication number
- JP2023548858A5 JP2023548858A5 JP2023526977A JP2023526977A JP2023548858A5 JP 2023548858 A5 JP2023548858 A5 JP 2023548858A5 JP 2023526977 A JP2023526977 A JP 2023526977A JP 2023526977 A JP2023526977 A JP 2023526977A JP 2023548858 A5 JP2023548858 A5 JP 2023548858A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- approximately
- seq
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110884P | 2020-11-06 | 2020-11-06 | |
| US63/110,884 | 2020-11-06 | ||
| US202163137972P | 2021-01-15 | 2021-01-15 | |
| US63/137,972 | 2021-01-15 | ||
| US202163173126P | 2021-04-09 | 2021-04-09 | |
| US63/173,126 | 2021-04-09 | ||
| US202163173919P | 2021-04-12 | 2021-04-12 | |
| US63/173,919 | 2021-04-12 | ||
| US202163174423P | 2021-04-13 | 2021-04-13 | |
| US63/174,423 | 2021-04-13 | ||
| US202163175440P | 2021-04-15 | 2021-04-15 | |
| US63/175,440 | 2021-04-15 | ||
| US202163219155P | 2021-07-07 | 2021-07-07 | |
| US202163203075P | 2021-07-07 | 2021-07-07 | |
| US202163203077P | 2021-07-07 | 2021-07-07 | |
| US63/203,075 | 2021-07-07 | ||
| US63/219,155 | 2021-07-07 | ||
| US63/203,077 | 2021-07-07 | ||
| PCT/US2021/058188 WO2022098955A1 (en) | 2020-11-06 | 2021-11-05 | Fcrn antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548858A JP2023548858A (ja) | 2023-11-21 |
| JP2023548858A5 true JP2023548858A5 (enExample) | 2024-11-14 |
Family
ID=81455198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526977A Pending JP2023548858A (ja) | 2020-11-06 | 2021-11-05 | Ｆｃｒｎ抗体及びその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220144946A1 (enExample) |
| EP (1) | EP4240417A4 (enExample) |
| JP (1) | JP2023548858A (enExample) |
| KR (1) | KR20230117575A (enExample) |
| AU (1) | AU2021376364A1 (enExample) |
| CA (1) | CA3200972A1 (enExample) |
| IL (1) | IL302516A (enExample) |
| JO (1) | JOP20230098A1 (enExample) |
| MX (1) | MX2023005313A (enExample) |
| PH (1) | PH12023551241A1 (enExample) |
| TW (1) | TW202233236A (enExample) |
| WO (1) | WO2022098955A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3081144A1 (en) | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| KR102904658B1 (ko) | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| US12202900B2 (en) | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| CN113518783A (zh) | 2018-07-20 | 2021-10-19 | 动量制药公司 | FcRn抗体组合物 |
| JP2023509195A (ja) | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | 天疱瘡症を治療する方法 |
| CN119698429A (zh) | 2022-06-15 | 2025-03-25 | 阿根思有限公司 | Fcrn结合分子及使用方法 |
| TW202421195A (zh) * | 2022-11-07 | 2024-06-01 | 比利時商阿根思公司 | 使用ｆｃｒｎ拮抗劑治療狼瘡性腎炎之方法 |
| WO2024163894A1 (en) * | 2023-02-04 | 2024-08-08 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating hemolytic disease of the fetus and newborn |
| TW202527982A (zh) * | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025163617A1 (en) * | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2025186787A1 (en) * | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
| WO2026083290A1 (en) * | 2024-10-16 | 2026-04-23 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS64768B1 (sr) * | 2015-01-30 | 2023-11-30 | Momenta Pharmaceuticals Inc | Fcrn antitela i načini njihove upotrebe |
| EP3518971A4 (en) * | 2016-09-28 | 2020-05-13 | Board Of Regents, The University Of Texas System | ANTIBODIES AND THERAPEUTIC PROTEIN FORMULATIONS AND USES THEREOF |
| CA3081144A1 (en) * | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| KR102904658B1 (ko) * | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| WO2020023310A1 (en) * | 2018-07-20 | 2020-01-30 | Williams Eva | Compositions of fcrn antibodies and methods of use thereof |
| CN113646051A (zh) * | 2018-10-16 | 2021-11-12 | Ucb生物制药有限责任公司 | 重症肌无力的治疗方法 |
| EP4007605A4 (en) * | 2019-08-01 | 2023-08-16 | Momenta Pharmaceuticals, Inc. | ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF |
-
2021
- 2021-11-05 IL IL302516A patent/IL302516A/en unknown
- 2021-11-05 AU AU2021376364A patent/AU2021376364A1/en active Pending
- 2021-11-05 EP EP21890118.9A patent/EP4240417A4/en active Pending
- 2021-11-05 US US17/519,811 patent/US20220144946A1/en active Pending
- 2021-11-05 MX MX2023005313A patent/MX2023005313A/es unknown
- 2021-11-05 CA CA3200972A patent/CA3200972A1/en active Pending
- 2021-11-05 WO PCT/US2021/058188 patent/WO2022098955A1/en not_active Ceased
- 2021-11-05 KR KR1020237018942A patent/KR20230117575A/ko active Pending
- 2021-11-05 PH PH1/2023/551241A patent/PH12023551241A1/en unknown
- 2021-11-05 JP JP2023526977A patent/JP2023548858A/ja active Pending
- 2021-11-05 TW TW110141386A patent/TW202233236A/zh unknown
-
2023
- 2023-05-04 JO JOJO/P/2023/0098A patent/JOP20230098A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023548858A5 (enExample) | ||
| CN103930444B (zh) | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 | |
| US20240417455A1 (en) | Treatment for rheumatoid arthritis | |
| US5741488A (en) | Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies | |
| CN107922507B (zh) | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 | |
| JP2025172841A5 (enExample) | ||
| JP2017160208A5 (enExample) | ||
| CA3118777A1 (en) | Methods of treating graves' ophthalmopathy using anti-fcrn antibodies | |
| KR20180132843A (ko) | Angptl8 억제제 및 angptl3 억제제로 고지혈증을 치료하는 방법 | |
| JP2021193121A (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| JP2022515770A5 (enExample) | ||
| US11248044B2 (en) | Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor | |
| KR20250084991A (ko) | 항-FcRN 항체를 이용한 만성 염증성 탈수초성 다발성 신경병증의 치료 방법 | |
| WO2019020069A1 (zh) | 一种sost抗体药物组合物及其用途 | |
| JP2025514142A5 (enExample) | ||
| JP6560808B2 (ja) | 抗（＋）メタンフェタミンモノクローナル抗体 | |
| US6436401B1 (en) | Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies | |
| CA3157797A1 (en) | Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies | |
| JP2024517087A5 (enExample) | ||
| JP7781519B2 (ja) | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 | |
| JP2024540435A5 (enExample) | ||
| JP2023531722A5 (enExample) | ||
| JP2022527542A5 (enExample) | ||
| CN119768431A (zh) | Igf1r抗体 | |
| WO2021018191A1 (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 |